MedPage Today

FDA Has Concerns on 'Unprecedented' Plan for Dostarlimab in Rectal Cancer

The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet Thursday and vote on whether the clinical development plans for dostarlimab (Jemperli) are sufficient to support accelerated approval of ...
Fox News

Rectal cancer drug trial of dostarlimab cures all patients: report

The results of a small clinical trial have found that there could be a cure for rectal cancer. The trial — conducted by Memorial Sloan Kettering Cancer Center in Manhattan — involved at least 12 ...

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or ...

GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for injection) in combination with chemotherapy (carboplatin and paclitaxel) for the ...
NBC New York

What Is Dostarlimab, the Drug Used in ‘Unprecedented' Cancer Trial?

A newly disclosed cancer study had "unprecedented" and "unheard-of" results, and now all eyes are on dostarlimab, the GlaxoSmithKline drug used to achieve complete remission in the trial. Developed by ...
Healio

ODAC: Single-arm trial data will suffice for dostarlimab in rectal cancer subgroup

Please provide your email address to receive an email when new articles are posted on . Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of ...
Monthly Prescribing Reference

FDA to Review Dostarlimab Plus Chemo for Expanded Endometrial Cancer Indication

In the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) has accepted ...
Business Insider

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 ...
MedPage Today

FDA Approves New Frontline Endometrial Cancer Regimen, First in Decades

The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced ...
Yahoo Finance

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of ...
Healio

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy can be used as an option to treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in ...